Γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Fu, Shibo ^a,b   Yang, Ying ^c   Tirtha, Das ^a   Yen, Yun ^d   Zhou, Bing sen ^d   Zhou, Ming Ming ^a   Ohlmeyer, Michael ^a   Ko, Eric C ^a   Cagan, Ross ^a   Rosenstein, Barry S ^a   Chen, Shu hsia ^a   Kao, Johnny ^a,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Good Samaritan Hospital Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H2AX; HYDROXYUREA; MS 0017509; MS 0019266; POLO LIKE KINASE 1; RADIOSENSITIZING AGENT; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER MODEL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA MICROARRAY; DNA REPAIR; DNA SYNTHESIS INHIBITION; DROSOPHILA; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; POLO LIKE KINASE 1 GENE; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DNA; DNA DAMAGE; DNA REPAIR; DROSOPHILA MELANOGASTER; DRUG EVALUATION, PRECLINICAL; EYE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; KINETICS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; RIBONUCLEOTIDE REDUCTASES; SMALL MOLECULE LIBRARIES;

EID: 84863084904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038465     Document Type: Article

References (38)

1. Connell PP, Kron SJ, Weichselbaum RR, (2004) Relevance and irrelevance of DNA damage response to radiotherapy. DNA Repair (Amst) 3: 1245-1251.
2. Janzen WP, (2001) High throughput screening: methods and protocols. Totowa, N.J.: Humana Press. ix, 265 p.
3. Lally BE, Geiger GA, Kridel S, Arcury-Quandt AE, Robbins ME, et al. (2007) Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library. Cancer Res 67: 8791-8799.
4. Katz D, Ito E, Liu FF, (2009) On the path to seeking novel radiosensitizers. Int J Radiat Oncol Biol Phys 73: 988-996.
5. Lang P, Yeow K, Nichols A, Scheer A, (2006) Cellular imaging in drug discovery. Nat Rev Drug Discov 5: 343-356.
6. Taylor DL, Haskins JR, Giuliano KA, (2006) High content screening: a powerful approach to systems cell biology and drug discovery. Totowa, N.J.: Humana Press.
7. Kao J, Rosenstein BS, Peters S, Milano MT, Kron SJ, (2005) Cellular response to DNA damage. Ann N Y Acad Sci 1066: 243-258.
8. Banath JP, Olive PL, (2003) Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 63: 4347-4350.
9. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, et al. (2003) Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278: 20303-20312.
10. Shiloh Y, Lehmann AR, (2004) Maintaining integrity. Nat Cell Biol 6: 923-928.
11. Kao J, Milano MT, Javaheri A, Garofalo MC, Chmura SJ, et al. (2006) gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets 6: 197-205.
12. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ, (2001) ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276: 42462-42467.
13. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM, (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868.
14. Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, et al. (2002) DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 4: 993-997.
15. Goldberg M, Stucki M, Falck J, D′Amours D, Rahman D, et al. (2003) MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 421: 952-956.
16. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, et al. (2000) A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10: 886-895.
17. Stucki M, Jackson SP, (2004) Tudor domains track down DNA breaks. Nat Cell Biol 6: 1150-1152.
18. Unal E, Arbel-Eden A, Sattler U, Shroff R, Lichten M, et al. (2004) DNA damage response pathway uses histone modification to assemble a double-strand break-specific cohesin domain. Mol Cell 16: 991-1002.
19. Xie A, Puget N, Shim I, Odate S, Jarzyna I, et al. (2004) Control of sister chromatid recombination by histone H2AX. Mol Cell 16: 1017-1025.
20. Taneja N, Davis M, Choy JS, Beckett MA, Singh R, et al. (2004) Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 279: 2273-2280.
21. Easmon J, Heinisch G, Purstinger G, Langer T, Osterreicher JK, et al. (1997) Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity. J Med Chem 40: 4420-4425.
22. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, et al. (2009) Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 52: 5271-5294.
23. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
24. Tannock IF, (1998) Conventional cancer therapy: promise broken or promise delayed? Lancet 351: SII9-16.
25. Seiwert TY, Salama JK, Vokes EE, (2007) The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4: 86-100.
26. Sarkaria JN, Eshleman JS, (2001) ATM as a target for novel radiosensitizers. Semin Radiat Oncol 11: 316-327.
27. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
28. Hou YN, Lavaf A, Huang D, Peters S, Huq R, et al. (2009) Development of an automated gamma-H2AX immunocytochemistry assay. Radiat Res 171: 360-367.
29. Cory JG, Downes DL, Cory AH, Schaper KJ, Seydel JK, (1994) Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth. Anticancer Res 14: 875-879.
30. Kunos CA, Chiu SM, Pink J, Kinsella TJ, (2009) Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiat Res 172: 666-676.
31. Strebhardt K, (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9: 643-660.
32. Gerster K, Shi W, Ng B, Yue S, Ito E, et al. (2010) Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 77: 253-260.
33. Katz D, Ito E, Lau KS, Mocanu JD, Bastianutto C, et al. (2008) Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. Biotechniques 44: ix-xiv.
34. Kainkaryam RM, Woolf PJ, (2009) Pooling in high-throughput drug screening. Curr Opin Drug Discov Devel 12: 339-50.
35. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
36. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
37. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
38. Vidal M, Wells S, Ryan A, Cagan R, (2005) ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 65: 3538-3541.